Related Experiment Videos
Calcitonin for myositis ossificans.
Rheumatology and Rehabilitation
|August 1, 1979
Summary
This case study explores myositis ossificans (MO) following cerebral hemorrhage. Salmon calcitonin treatment showed potential joint range improvement and halted ectopic calcification, but its effectiveness remains unproven due to MO's natural course.
Area of Science:
- Neurology
- Orthopedics
- Pharmacology
Background:
- Myositis ossificans (MO) is a condition characterized by heterotopic ossification.
- It can occur secondary to trauma or neurological events like cerebral hemorrhage.
- Hemiparesis following cerebral hemorrhage can increase the risk of MO development.
Observation:
- A patient developed myositis ossificans after experiencing hemiparesis due to a cerebral hemorrhage.
- The patient was treated with synthetic salmon calcitonin.
- Clinical observation noted an improvement in the affected joint's range of motion.
Findings:
- Synthetic salmon calcitonin administration appeared to halt further ectopic calcification in the affected muscles.
- A positive trend in joint mobility was observed during the treatment period.
- The natural remitting course of myositis ossificans makes definitive conclusions about calcitonin's efficacy challenging.
Implications:
- This case suggests a potential role for salmon calcitonin in managing myositis ossificans, particularly in preventing further ectopic calcification.
- Further controlled studies are warranted to establish the therapeutic efficacy of calcitonin in myositis ossificans.
- Understanding the interplay between neurological injury and heterotopic ossification is crucial for developing targeted treatments.